⚠️ Ibogaine can induce intense, prolonged psychedelic experiences lasting 18–36 hours. Unscreened or mismanaged psychiatric conditions — including undisclosed bipolar disorder, active psychosis, or severe trauma histories — have been associated with psychological crises, prolonged psychotic episodes, and in rare cases, treatment dropout requiring emergency psychiatric intervention. Skipping psychological screening is not a minor oversight; it is a documented safety risk.

Psychological Screening for Ibogaine Candidates

Psychological screening is one of the two pillars of ibogaine safety — the other being cardiac screening. While much public attention focuses on ibogaine's cardiac risks (particularly QTc prolongation), the psychological demands of the experience are equally serious and require systematic pre-treatment evaluation. Reputable clinical protocols worldwide treat psychological screening as mandatory, not optional.

This page explains what responsible screening looks like, which conditions are contraindicated or require special caution, what happens when screening is skipped, and what you should expect from any legitimate provider.

Why Psychological Screening Is Non-Negotiable

Ibogaine produces a prolonged, non-ordinary state of consciousness characterized by intense visual and auditory phenomena, autobiographical memory replay, and what many participants describe as forced confrontation with unresolved psychological material (Noller et al., 2018). For someone with a well-integrated psyche and adequate psychological resilience, this can be profoundly therapeutic. For someone with active psychosis, unmanaged bipolar I disorder, or severe unprocessed trauma, the same experience can precipitate a psychiatric emergency.

Unlike shorter-acting psychedelics, ibogaine's active phase cannot be quickly terminated. There is no established reversal agent. If a participant decompensates psychologically mid-experience, the clinical team must manage an acute psychiatric crisis in a person who is also in an altered neurological state — a situation that demands both prevention through screening and readiness through trained staff.

A 2021 systematic review of ibogaine adverse events found that psychological adverse events — including acute psychosis, PTSD re-traumatization, and prolonged altered states — were underreported relative to cardiac events but represented a meaningful proportion of serious treatment complications (Brown & Alper, 2018; Ona et al., 2021).

Absolute Psychological Contraindications

The following conditions are considered absolute contraindications in most rigorous clinical protocols, including those used at licensed ibogaine clinics in New Zealand, Portugal, and Mexico:

  • Active or recent (within 12 months) psychosis — including schizophrenia, schizoaffective disorder, and substance-induced psychotic disorder not fully resolved
  • Bipolar I disorder with active or recent manic or mixed episodes — ibogaine's stimulating and serotonergic properties can trigger or worsen mania
  • Active suicidal ideation with plan or intent — not passive ideation alone, but imminent risk; many protocols require no active suicidality within 30–90 days
  • Severe untreated dissociative identity disorder (DID) — the forced introspective state can be destabilizing without extensive preparatory trauma work
  • Acute delirium or active encephalopathy from any cause

These are not provisional cautions — they represent conditions under which responsible practitioners will decline to administer ibogaine regardless of patient preference or willingness to sign waivers.

Relative Contraindications Requiring Enhanced Screening

The following conditions do not automatically disqualify a candidate but require deeper evaluation, stabilization, and often additional safeguards before treatment proceeds:

  • Bipolar II disorder or cyclothymia — requires mood stabilization and careful timing; current mood state must be stable, not hypomanic
  • Post-traumatic stress disorder (PTSD) — ibogaine can forcefully surface traumatic memories; preparatory trauma therapy and robust aftercare planning are strongly recommended (Davis et al., 2020)
  • Major depressive disorder (MDD) — passive suicidal ideation, severe anhedonia, and hopelessness should be carefully assessed; some evidence supports ibogaine's antidepressant properties but safety data in severe MDD is limited
  • Borderline personality disorder (BPD) — emotional dysregulation and identity disturbance can be intensified; experienced clinical support and strong therapeutic alliance are required
  • Anxiety disorders, including panic disorder and OCD — can intensify during the acute experience; anxiolytic pre-medications may be contraindicated due to interactions, so careful planning is essential
  • History of psychosis without current symptoms — vulnerability to re-emergence under psychedelic states requires individual risk assessment
  • Severe trauma history including childhood abuse or complex PTSD (C-PTSD) — requires preparatory therapy and robust integration support
  • Eating disorders with active medical complications — electrolyte imbalances from purging create both cardiac and neurological risks compounding psychological risk
  • Current benzodiazepine or alcohol dependence — withdrawal during treatment creates dangerous physiological overlap; must be managed medically before ibogaine administration

What Comprehensive Psychological Screening Should Include

Any legitimate ibogaine provider should conduct — or require documentation of — the following elements before admission:

Structured Clinical Interview

A licensed mental health professional (psychiatrist, psychologist, or licensed clinical social worker with relevant training) should conduct a structured diagnostic interview, ideally using validated tools such as the SCID-5 (Structured Clinical Interview for DSM-5) or MINI International Neuropsychiatric Interview. This is not replaceable by a self-report questionnaire alone.

Validated Assessment Tools

Responsible screening incorporates validated instruments appropriate to the presenting concerns, which may include:

  • PHQ-9 — depression severity
  • GAD-7 — anxiety severity
  • PCL-5 — PTSD symptom checklist
  • MDQ (Mood Disorder Questionnaire) — screening for bipolar spectrum conditions
  • Columbia Suicide Severity Rating Scale (C-SSRS) — suicide risk stratification
  • AUDIT / DAST-10 — substance use severity
  • DES-II — dissociative experiences, if clinically indicated

Psychiatric History Review

This includes prior diagnoses, hospitalizations, medication history (including psychotropics), prior psychedelic experiences and responses, family history of psychotic illness, and any history of adverse reactions to anesthesia or dissociative substances.

Current Medication Review

Psychological screening cannot be separated from pharmacological screening. Several psychiatric medications carry serious interaction risks with ibogaine:

  • SSRIs and SNRIs — serotonin syndrome risk; most protocols require a washout period of at least 2 weeks (5+ weeks for fluoxetine/Prozac due to long half-life) under medical supervision
  • MAOIs — absolute contraindication; ibogaine itself has mild MAOI-like properties; combination is potentially fatal
  • Lithium — lowers seizure threshold; ibogaine interaction risk; must be tapered and discontinued under psychiatric supervision
  • Antipsychotics (typical and atypical) — blunt the ibogaine experience unpredictably; some (e.g., haloperidol, quetiapine) have QTc-prolonging properties compounding cardiac risk
  • Benzodiazepines — reduce ibogaine efficacy; physical dependence requires medically supervised taper before treatment, which itself takes weeks to months
  • Tramadol — lowers seizure threshold and has serotonergic properties; contraindicated
  • Stimulants (amphetamines, methylphenidate) — cardiovascular and CNS interaction risks; must be discontinued with appropriate washout

Never discontinue psychiatric medications abruptly or without the guidance of a prescribing physician. Abrupt SSRI discontinuation causes withdrawal syndromes; abrupt benzodiazepine or alcohol cessation can be life-threatening.

Trauma History and Resilience Assessment

Beyond formal diagnosis, skilled screeners assess a candidate's psychological resilience — their capacity to tolerate distress, access support, and integrate difficult experiences. This includes:

  • History of prior trauma and how it has been processed
  • Current therapeutic support and quality of therapeutic relationship
  • Social support network
  • History of managing difficult psychological states (nightmares, flashbacks, dissociation)
  • Motivation for treatment and expectations (which directly affect psychological outcomes)

Capacity and Informed Consent Assessment

Screeners should assess whether the candidate has the cognitive and psychological capacity to provide genuine informed consent — understanding the nature of the experience, its risks, and realistic expectations. Candidates in acute crisis, severe depression with cognitive impairment, or under coercive pressure from family or courts require careful assessment of consent validity.

The Role of Preparation in Psychological Safety

Even candidates who pass all screening criteria benefit substantially from preparatory psychological work. Research on psychedelic-assisted therapy consistently shows that preparation ("set" preparation) is a major determinant of outcome and safety (Carhart-Harris et al., 2018). For ibogaine specifically, this means:

  • At minimum 1–3 preparatory sessions with a therapist or counselor experienced in psychedelic work
  • Establishing clear intentions and therapeutic goals
  • Developing a plan for managing challenging experiences during the session ("difficult experience protocol")
  • Identifying and preparing for likely psychological content likely to arise (e.g., known unresolved grief, trauma)
  • Establishing a detailed aftercare and integration plan before treatment begins

Ibogaine clinics that offer only a brief intake call or online questionnaire before treatment — with no substantive psychological preparation — represent a red flag for inadequate safety standards.

What Happens When Psychological Screening Is Skipped or Inadequate

Documented consequences of inadequate psychological screening include:

  • Acute psychotic episodes during or following the ibogaine experience, requiring emergency psychiatric hospitalization. Several case reports exist of ibogaine-precipitated psychosis in individuals with undisclosed or unrecognized bipolar disorder (Schenberg et al., 2014).
  • Severe PTSD re-traumatization without adequate containment or integration support, resulting in worsened PTSD symptoms, increased suicidality, and functional deterioration post-treatment
  • Prolonged perceptual disturbances — sometimes called Hallucinogen Persisting Perception Disorder (HPPD) — more commonly reported in individuals with pre-existing anxiety disorders or prior adverse psychedelic reactions
  • Serotonin syndrome in candidates who did not disclose or fully taper SSRIs before treatment, ranging from mild (agitation, diaphoresis) to life-threatening (hyperthermia, seizures, cardiovascular instability)
  • Lithium-related seizures — there are documented fatalities associated with ibogaine administered to individuals who had not discontinued lithium (Alper et al., 2012)
  • Suicide in the post-treatment period — while ibogaine has demonstrated anti-suicidal properties in some research, the post-treatment integration period carries elevated risk for individuals with inadequate psychological support, particularly those with PTSD or severe depression whose symptoms temporarily worsen before improving

Questions to Ask Any Ibogaine Provider

Before committing to a program, candidates and their families should ask providers the following directly:

  • Who conducts your psychological screening — what are their credentials and training?
  • Which validated assessment tools do you use?
  • Do you require a washout period from psychiatric medications, and how do you support candidates through that process?
  • What is your protocol if someone decompensates psychologically during or after treatment?
  • Do you have a relationship with an emergency psychiatric facility?
  • What integration support is provided after treatment, and for how long?
  • Can I provide records from my treating psychiatrist or psychologist, and will your team review them?

Providers who deflect, minimize, or provide vague answers to these questions should be considered with serious caution.

Psychological Screening in Licensed vs. Unregulated Settings

Ibogaine is currently Schedule I in the United States, making it illegal outside of FDA-approved research protocols. Licensed treatment occurs in countries including New Zealand (where ibogaine is regulated as a prescription medicine), Portugal, Mexico, Canada (through special access), and several others. In licensed settings, psychological screening requirements are typically codified in clinical protocols and subject to regulatory oversight.

Underground or informal settings vary enormously — some maintain rigorous standards, many do not. Candidates pursuing treatment in unregulated contexts carry substantially greater risk of inadequate psychological screening, and bear greater personal responsibility for vetting the provider's competence. The absence of regulatory oversight does not mean safety screening is optional; it means candidates must perform more due diligence themselves.

Frequently Asked Questions

No — a history of depression that is currently well-managed and stable is not automatically disqualifying. The key factors screeners assess are: your current symptom severity, whether you have active suicidal ideation, whether you are on antidepressants (which require a supervised washout), and the robustness of your support system. Many people with depression histories have received ibogaine treatment safely with appropriate preparation and monitoring. However, severe depression with cognitive impairment or recent suicidality requires much more cautious evaluation and may defer or disqualify treatment depending on individual clinical judgment.
Most rigorous clinical protocols require a minimum of 2 weeks off SSRIs and SNRIs, and a minimum of 5–6 weeks off fluoxetine (Prozac) due to its exceptionally long half-life and active metabolite. This washout is necessary to reduce serotonin syndrome risk. Critically, you should never stop antidepressants abruptly or without guidance from your prescribing physician — SSRI discontinuation syndrome can be severe, and some individuals require a slow taper over months. The washout period should be supervised and should itself be considered part of your pre-treatment protocol. Ask any candidate ibogaine provider whether they coordinate with your prescribing doctor during the washout phase; this is a marker of program quality.
PTSD is a relative contraindication — not an automatic disqualifier — but it requires serious attention. Early research, including work by Davis et al. (2020) and studies with veterans, has shown potential benefit for PTSD with ibogaine, but the same mechanism that may help — forced confrontation with autobiographical memory — can also temporarily intensify trauma symptoms, trigger dissociative episodes, or surface previously suppressed memories without adequate containment. The difference between a therapeutic and a harmful outcome often comes down to: (1) the quality of preparatory trauma work done before treatment, (2) the skill and trauma-competence of the clinical team present, and (3) the quality and duration of post-treatment integration support. Individuals with severe, untreated, or complex PTSD should engage in substantial preparatory therapy before any psychedelic treatment, ibogaine included.
This is one of the most dangerous things a candidate can do. Concealing a diagnosis like bipolar disorder, a psychosis history, or active SSRI use doesn't eliminate the risk those conditions create — it just ensures the clinical team has no ability to prepare for or respond to those risks. Documented cases of ibogaine-precipitated psychotic episodes and serotonin syndrome have involved individuals who did not disclose relevant psychiatric history. Beyond the personal safety risk, it may also void any medical support the facility could otherwise provide in an emergency, and in some jurisdictions creates legal liability issues. If you are concerned that disclosure will disqualify you, discuss your concerns honestly with the provider — some conditions that seem disqualifying can be addressed with additional preparation, stabilization, or modified protocols. Misrepresentation cannot be undone once the experience has begun.
Integration refers to the therapeutic and lifestyle work done after the ibogaine experience to process, understand, and anchor insights into lasting change. It is not optional from a safety perspective. The post-ibogaine period — typically the first 4–12 weeks — is a psychologically vulnerable window. Neuroplasticity is elevated (Bhatt et al., 2024), which means both positive change and destabilization are more likely. Integration support typically includes scheduled sessions with a therapist familiar with psychedelic experiences, peer support groups, journaling practices, somatic work, and practical lifestyle planning. Individuals with histories of trauma, mood disorders, or severe addiction are at elevated risk of psychological deterioration without integration support. A responsible provider will have a post-treatment integration protocol established before treatment begins — not as an afterthought. Red flag: any provider who considers their responsibility complete when you leave the clinic.
A brief video call intake — especially one conducted by non-clinical staff — is not sufficient psychological screening by established safety standards. Comprehensive screening requires a structured clinical interview conducted by a licensed mental health professional, validated assessment instruments, review of prior psychiatric and medical records, and ideally multiple contacts over time to assess stability. A single call can flag obvious contraindications but will miss nuanced presentations of bipolar disorder, concealed trauma histories, or evolving suicidality. If a provider's entire psychological screening consists of one call and a self-report form, that is a meaningful safety gap and should be weighed seriously in your decision-making. The most rigorous programs require documentation from a treating psychiatrist or psychologist in addition to their own evaluation.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.